Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Predictive Value of Dynamic Contrast Enhancement MRI on a Cerebral Tumor Response to Gamma Knife Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Université de Sherbrooke.
Recruitment status was  Recruiting
Information provided by:
Université de Sherbrooke Identifier:
First received: September 7, 2005
Last updated: February 6, 2006
Last verified: September 2005

Hypothesis: the pattern of MRI contrast enhancement after gadolinium injection is different in tumors that respond well to gamma knife.

We are going to acquire sequential T1-weighted images of brain lesions before, during and after injection of Gd-DTPA. This will be repeated before and after a treatment with gamma knife. We will then analyse our results to see if there are common enhancement characteristics between lesions that will respond well to the radiosurgery treatment.

Cerebral Metastases

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: Prospective Study of Predictive Value of Dynamic Contrast Enhancement Magnetic Resonance Imaging With Gadolinium on the Response of a Cerebral Tumor to a Treatment With Gamma Knife

Resource links provided by NLM:

Further study details as provided by Université de Sherbrooke:

Estimated Enrollment: 30
Study Start Date: August 2005
Estimated Study Completion Date: June 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with intracerebral lesion benign or malignant wich are not concerned by the exclusion criteria

Exclusion Criteria:

  • Pancranial radiotherapy
  • Residual postop lesion
  • Gliomas
  • Patients < 18 years old
  • Anterior allergic reaction to gadolinium
  • Claustrophobia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00156585

Contact: Brendan Kenny, MD 1-819-346-1110 ext 14962
Contact: Chenard Jean, MD 1-819-346-1110 ext 14962

Canada, Quebec
Faculté de médecine, Université de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Chenard Jean, MD    1-819-346-1110 ext 14962      
Contact: Martin Lepage, PhD    1-819-346-1110 ext 11867      
Principal Investigator: Chenard Jean, MD         
Sponsors and Collaborators
Université de Sherbrooke
Principal Investigator: Jean Chenard, MD University of Sherbrooke
  More Information

No publications provided Identifier: NCT00156585     History of Changes
Other Study ID Numbers: 05-063
Study First Received: September 7, 2005
Last Updated: February 6, 2006
Health Authority: Canada: Health Canada

Keywords provided by Université de Sherbrooke:
cerebral metastases
dynamic contrast enhanced magnetic resonance imaging
gamma knife

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes processed this record on November 20, 2014